Check for updates

BRIEF REPORT

REVISÉ Mitochondrial dysfunction in an animal model of diabetic neuropathy is associated with a reduction of neurosteroid synthesis. [version 2; peer review: 2 approved]

Stephen R. Humble ^{1,2}

¹Department of Anaesthetics and Pain Management, Charing Cross Hospital, Imperial College NHS Healthcare Trust London, London, W6 8RF, UK

²Imperial College London, Charing Cross Campus, Margravine Road, London, W6 8RP, UK

v2 First published: 18 Apr 2017, 6:506
<https://doi.org/10.12688/f1000research.11056.1>

Latest published: 09 Mar 2018, 6:506
<https://doi.org/10.12688/f1000research.11056.2>

Abstract

Background: Recent work in a model of diabetic neuropathy revealed that layer 2/3 cortical pyramidal neurones of the pain pathway exhibited reduced endogenous neurosteroid modulation of the GABA_AR and exogenously applied neurosteroids had an exaggerated impact. It is postulated that this is related to reduced precursor synthesis, due to mitochondrial dysfunction in diabetic neuropathy. Benzodiazepines are also known to activate neurosteroidogenesis by binding to mitochondrial translocator protein (TSPO). This study explored the differential effect of diazepam on GABA_AR modulation via neurosteroidogenesis in diabetic and wild type (WT) mice.

Methods: Whole-cell patch-clamp technique was used on slices of neural tissue. Electrophysiological recordings were obtained from layer 2/3 cortical pyramidal neurons of the pain pathway from mice with type-II diabetic neuropathy (*ob/ob*) and WT controls aged 60-80 days.

Results: There was a key difference in the response of the WT and *ob/ob* cortical neurons to simultaneous incubation with diazepam and flumazenil. In contrast, diazepam and the 5 α -reductase inhibitor finasteride, individually or in combination, produced the same response in both strains.

Conclusions: The exaggerated effect of diazepam on GABAergic inhibitory tone in the *ob/ob*, despite the presence of the GABA_AR benzodiazepine antagonist flumazenil is likely observed due to physiological upregulation of key neurosteroidogenic enzymes in response to the reduced pregnenolone synthesis by the mitochondria. By increasing pregnenolone via TSPO activation, it is possible to promote enhanced neurosteroidogenesis and increase GABAergic inhibitory tone via an alternate route. In diabetic neuropathy, mitochondrial dysfunction may play an important role. Enhancing the GABAergic neurosteroid tone could be of potential therapeutic

Open Peer Review

Approval Status

	1	2
version 2 (revision) 09 Mar 2018		
version 1 18 Apr 2017	 view	 view

1. **Slobodan M. Todorovic**, University of Colorado Anschutz Medical Campus, Aurora, USA

2. **Pascal Darbon** , Centre National de la Recherche Scientifique and University of Strasbourg, Strasbourg Cedex, France

Any reports and responses or comments on the article can be found at the end of the article.

benefit.

Keywords

Diabetes, neuropathic, pain, neurosteroid, benzodiazepine, ob/ob, mitochondria, TSPO, GABA

Corresponding author: Stephen R. Humble (stephen.humble@nhs.net)

Author roles: Humble SR: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Software, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This research was supported by the Wellcome Trust (090667).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2018 Humble SR. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Humble SR. **Mitochondrial dysfunction in an animal model of diabetic neuropathy is associated with a reduction of neurosteroid synthesis. [version 2; peer review: 2 approved]** F1000Research 2018, 6:506

<https://doi.org/10.12688/f1000research.11056.2>

First published: 18 Apr 2017, 6:506 <https://doi.org/10.12688/f1000research.11056.1>

REVISED Amendments from Version 1

Changes have been made in response to comments made by the reviewers. The title has been made more specific to the data presented. In the Abstract, "neuropathic pain" has been changed to "neuropathy" as the concept of *pain* is specific to humans, in contrast to *nociception*, which applies to mice and other species including humans. The Discussion has been edited to facilitate the reader's understanding by putting the data in the context of recent work (Humble, 2016a). Similarly, Figure 1 and its legend have been edited in order to highlight action sites of diazepam, flumazenil and finasteride and therefore enhance readability. We have removed the mention of Dr Ladas from the Acknowledgements section, as this was accidentally added to the version 1.

See referee reports

Introduction

Diabetic neuropathy is a common cause of painful neuropathy, and treatment is often suboptimal because the underlying aetiology is poorly understood. Peripheral and central sensitisation are implicated in the development of neuropathic pain with neuroplasticity occurring at multiple levels of the pain pathway (Harvey & Dickenson, 2008). GABAergic neurones at all levels of the pain pathway have a vital role in the transmission of painful stimuli in the perception of pain itself (D'Mello & Dickenson, 2008). Endogenous and exogenous neurosteroids may act as potent positive allosteric modulators of GABA_A receptors (GABA_ARs) and consequently exhibit analgesic, anxiolytic, anticonvulsant, and sedative properties (D'Hulst *et al.*, 2009).

Within inhibitory synapses, the presynaptic fusion of a single vesicle releases the inhibitory neurotransmitter GABA to activate synaptic GABA_ARs. Under voltage-clamp conditions this causes a miniature inhibitory postsynaptic current (mIPSC). Drugs that enhance GABA_AR function cause a prolongation of the mIPSC decay phase. Recent work in a model of type-II diabetic neuropathy (*ob/ob*) revealed that layer 2/3 cortical pyramidal neurones of the pain pathway exhibited reduced endogenous neurosteroid modulation of the GABA_AR, and exogenously applied neurosteroids had an exaggerated impact (Humble, 2016a). The mechanism responsible appeared unrelated to GABA_AR sensitivity, but instead was associated with a reduction of neurosteroid precursors, such as pregnenolone, which is metabolised sequentially to the active compound allopregnanolone (Figure 1) (Humble, 2013; Humble, 2016a). Pregnenolone is synthesised in the mitochondrion from its precursor cholesterol by the side chain cleavage enzyme P450 located in the inner mitochondrial membrane (Do Rego *et al.*, 2009; Schumacher *et al.*, 2012), and it is postulated that diabetic neuropathy may be associated with a

reduction in mitochondrial activity. Cholesterol is translocated across the mitochondrial membrane by the 18 kDa translocator protein (TSPO) in a coordinated fashion with the steroidogenic acute regulatory (StAR) protein (Do Rego *et al.*, 2009; Gatliff & Campanella, 2016; Rupprecht *et al.*, 2010; Stocco *et al.*, 2017; Figure 1).

The present study explored the impact of the benzodiazepine diazepam, a positive allosteric modulator of the GABA_AR (D'Hulst *et al.*, 2009), on GABA_AR modulation via neurosteroidogenesis in diabetic and wild type (WT) mice. Benzodiazepines are also known to activate neurosteroidogenesis by binding to TSPO (Rupprecht *et al.*, 2010; Tokuda *et al.*, 2010).

Methods

The methods are identical to those published by the same author previously (Humble, 2016a), with the exception of the drugs diazepam and flumazenil, which were not used in the previous study. Diazepam and flumazenil were purchased (Tocris, Bristol UK) and prepared as concentrated stock solutions in dimethyl sulfoxide before being added to the artificial extracellular solution as per the previous study (Humble, 2016a).

Results

Prolonged exposure (2 hrs) of mature cortical neurones to diazepam (1 μ M) in the presence of flumazenil had an exaggerated effect on the cortical GABA_AR-mediated mIPSCs of *ob/ob* mice in comparison to WT mice

Whole-cell voltage-clamp recordings were made in L2/3 cortical neurones of WT and *ob/ob* mice after at least two hours of incubation with diazepam, flumazenil and finasteride. Diazepam alone had the same effect on both strains of mice. In the WT mice, flumazenil inhibited the effect of diazepam (τ_w : control = 4.0 ± 0.1 ms, $n = 35$; finasteride 50 μ M = 4.2 ± 0.1 ms, $n = 7$; diazepam 1 μ M = 5.9 ± 0.2 ms, $n = 6$; flumazenil 10 μ M & diazepam 1 μ M = 4.0 ± 0.2 ms, $n = 7$; flumazenil 10 μ M, finasteride 50 μ M & diazepam 1 μ M = 4.0 ± 0.3 ms, $n = 6$; One-way ANOVA, $P < 0.05$; *post hoc* Newman Keul's test revealed a difference only for diazepam 1 μ M, $P < 0.05$; Figure 2). By contrast, in the *ob/ob* mice, flumazenil only partially inhibited the effect of diazepam, and the persisting effect of diazepam in the presence of flumazenil in the *ob/ob* mice could be prevented by the presence of the 5 α -reductase enzyme inhibitor finasteride (τ_w : *ob/ob* control = 3.5 ± 0.1 ms, $n = 25$; finasteride 50 μ M = 3.7 ± 0.2 ms, $n = 6$; diazepam 1 μ M = 5.7 ± 0.3 ms, $n = 6$; flumazenil 10 μ M & diazepam 1 μ M = 4.9 ± 0.3 ms, $n = 6$; flumazenil 10 μ M, finasteride 50 μ M & diazepam 1 μ M = 3.7 ± 0.1 ms, $n = 5$; One-way ANOVA, $P < 0.05$; *post hoc* Newman Keul's test revealed significant intergroup differences for the flumazenil groups, $P < 0.05$; Figure 2).

Figure 1. Modulation of the GABA_AR by endogenous neurosteroids. Cholesterol is taken through the mitochondrial membrane by the translocator protein (TSPO) where it is converted to pregnenolone by the cytochrome P450 side chain cleavage enzyme. Pregnenolone is converted to progesterone by 3β-hydroxysteroid dehydrogenase (3β-HSD), which is in turn reduced to dihydroxyprogesterone by 5α-reductase (5α-R). Dihydroxyprogesterone is converted to allopregnanolone by 3α-hydroxysteroid dehydrogenase (3α-HSD). Postsynaptic GABA_ARs are activated by GABA that has been released from vesicles in the presynaptic nerve terminal. GABA induces a conformational change of the GABA_AR, opening its central channel and thereby allowing the passage of chloride ions and the subsequent generation of miniature inhibitory postsynaptic currents (mIPSCs). The negative chloride ions induce hyperpolarisation of the neuronal membrane, which mediates neuronal inhibition. Neurosteroids, such as the active compound allopregnanolone, modulate GABA_AR function and facilitate inhibition of the neuronal membrane. (Humble, 2013). The translocation of cholesterol into the mitochondria by TSPO is the first rate-limiting step and is enhanced by the presence of specific ligands such as diazepam. Thus diazepam may enhance GABA_AR modulation by binding to the GABA_AR directly and separately by increased neurosteroidogenesis. This modulation may be selectively inhibited at the GABA_AR itself by the antagonist flumazenil and separately by the 5α-R inhibitor finasteride, which inhibits neurosteroidogenesis.

Figure 2. Prolonged exposure (2 hrs) of mature cortical neurones to diazepam (1 µM) in the presence of flumazenil had an exaggerated effect on the cortical GABA_AR-mediated mIPSCs of *ob/ob* mice in comparison to WT mice. (A) Superimposed exemplar averaged GABA_AR-mediated miniature inhibitory postsynaptic currents (mIPSCs) acquired from a representative WT cortical neurone and from equivalent neurones after ~2 hours pre-incubation of the brain slice with diazepam (1 µM), flumazenil (10 µM) and finasteride (50 µM). (B) Superimposed exemplar averaged GABA_AR-mediated mIPSCs acquired from a representative *ob/ob* cortical neurone and from equivalent neurones after ~2 hours pre-incubation of the brain slice with diazepam (1 µM), flumazenil (10 µM) and finasteride (50 µM). (C) Histogram illustrating that flumazenil is able to prevent the effect of diazepam to prolong the duration of the GABA_AR-mediated mIPSC in WT cortical neurones, but only has a partial efficacy in *ob/ob* cortical neurones (τ_w in ms; one-way ANOVA, *P* > 0.05; *Post hoc* Newman Keul's test). The persisting effect of diazepam in the presence of flumazenil in the *ob/ob* mice could be prevented by the presence of the 5α-reductase enzyme inhibitor finasteride (τ_w in ms; one-way ANOVA, *P* > 0.05; *Post hoc* Newman Keul's test). Ctrl = control; Finast = finasteride; Diaz = diazepam; Flumaz = flumazenil.

Discussion

Layer 2/3 cortical neurones from mature type-II diabetic *ob/ob* are known to have a reduced endogenous pregnane-derived neurosteroid tone in comparison to strain matched WT controls (Humble, 2016a). The present data indicate that by promoting the uptake of pregnenolone's precursor cholesterol by the mitochondria, via TSPO, diazepam may rescue the reduced neurosteroid tone. The restored neurosteroid tone could re-establish GABA_AR-mediated neuro-inhibitory tone in cases of neuropathic hypersensitivity. With specific reference to these data, the key result is the difference in response of the WT and *ob/ob* to simultaneous incubation with diazepam and flumazenil. In contrast, diazepam and the 5α-reductase inhibitor finasteride individually or in combination produced the same response in both WT and *ob/ob*. This may be interpreted as follows: in the WT, the primary effect of diazepam incubation is direct allosteric modulation of the GABA_AR, with negligible contribution from neurosteroidogenesis via mitochondrial TSPO activation. In comparison, diazepam

has an exaggerated effect on GABAergic inhibitory tone in the *ob/ob*, despite the presence of the GABA_AR benzodiazepine antagonist flumazenil. This effect is likely observed due to physiological upregulation of the key rate-limiting enzymes involved in neurosteroidogenesis in response to the reduced pregnenolone synthesis by the mitochondria (Figure 1; Humble, 2016a). Thus by increasing the availability of the neurosteroid precursor pregnenolone via TSPO activation, it is possible to promote enhanced neurosteroidogenesis and thereby increase GABAergic inhibitory tone via an alternate route. Benzodiazepines modulate the GABA_AR by binding to the α-γ subunit interface (D'Hulst *et al.*, 2009), while neurosteroids bind the GABA_AR from a cavity within the α-subunit domain and modulate it directly via the α-β subunit interface (Hosie *et al.*, 2006). There have already been a number of other studies of ligands for the mitochondrial TSPO, as this is a promising target (Gatliff & Campanella, 2016; Giatti *et al.*, 2009; Papadopoulos & Lecanu, 2009; Rupprecht *et al.*, 2010; Zhang *et al.*, 2016). Considering the findings in this paper

alongside previous work (Humble, 2016a) it appears that mitochondrial dysfunction may play an important role in the development of type 2 diabetic neuropathy. In this context, it follows that enhancing the GABAergic neurosteroid tone directly or indirectly could be of potential therapeutic benefit for diabetic neuropathic pain and hypersensitivity.

Data availability

Open Science Framework: Dataset of 'Neurosteroids are reduced in diabetic neuropathy and may be associated with the development of neuropathic pain', doi: [10.17605/osf.io/bk3tw](https://doi.org/10.17605/osf.io/bk3tw) (Humble, 2016b). Raw data for the present study can be found in Diazepam.zip.

Please refer to (Humble, 2016a) for details of standard software used for data analysis.

Author contributions

Dr Stephen Humble is responsible for this all work, including planning the experiments, performing the experiments and writing the paper. Prof Hales and Lambert, and Dr Belelli assisted Dr Humble with regards to the planning of some experiments.

Supplementary material

Supplementary Tables 1 and 2: Analysed raw data.

[Click here to access the data.](#)

However, after discussion it was decided that their contributions merited being listed in the Acknowledgements section rather than as co-authors.

Competing interests

No competing interests were disclosed.

Grant information

This research was supported by the Wellcome Trust (090667).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements

I am indebted to the generous support of the Wellcome Trust and would also like to thank: Prof Hales, Dr Belelli, Dr McCrimmon, Prof Peters, Prof Sillar, Dr Connolly, Dr Miles, Prof Poisbeau, Prof Lambert for their scientific advice, Miss Gallacher, Miss Wright, Dr McLeod, Mr McLeod, Dr Newman, Dr Cooper, Dr Brown, Dr Panetta, Dr Livesey for their technical assistance, Prof Matthews, Dr Moffat, Mr F Kafka, Prof P Anand, Dr P Donatien, Dr R Privitera, Dr Y Yangou, Prof A Dickenson, Dr Platt, Dr Jenner, Dr Bhaskar, Dr Kontouli, Dr Feynman, Mrs E Humble for their support.

References

- D'Hulst C, Atack JR, Kooy RF: **The complexity of the GABA_A receptor shapes unique pharmacological profiles.** *Drug Discov Today*. 2009; 14(17–18): 866–875. [PubMed Abstract](#) | [Publisher Full Text](#)
- D'Mello R, Dickenson AH: **Spinal cord mechanisms of pain.** *Br J Anaesth*. 2008; 101(1): 8–16. [PubMed Abstract](#) | [Publisher Full Text](#)
- Do Rego JL, Seong JY, Burel D, *et al.*: **Neurosteroid biosynthesis: enzymatic pathways and neuroendocrine regulation by neurotransmitters and neuropeptides.** *Front Neuroendocrinol*. 2009; 30(3): 259–301. [PubMed Abstract](#) | [Publisher Full Text](#)
- Gatliff J, Campanella M: **TSPO: kaleidoscopic 18-kDa amid biochemical pharmacology, control and targeting of mitochondria.** *Biochem J*. 2016; 473(2): 107–21. [PubMed Abstract](#) | [Publisher Full Text](#)
- Giatti S, Pesaresi M, Cavaletti G, *et al.*: **Neuroprotective effects of a ligand of translocator protein-18 kDa (Ro5-4864) in experimental diabetic neuropathy.** *Neuroscience*. 2009; 164(2): 520–529. [PubMed Abstract](#) | [Publisher Full Text](#)
- Harvey VL, Dickenson AH: **Mechanisms of pain in nonmalignant disease.** *Curr Opin Support Palliat Care*. 2008; 2(2): 133–139. [PubMed Abstract](#) | [Publisher Full Text](#)
- Hosie AM, Wilkins ME, da Silva HM, *et al.*: **Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites.** *Nature*. 2006; 444(7118): 486–489. [PubMed Abstract](#) | [Publisher Full Text](#)
- Humble S: **Dataset of 'Neurosteroids Are Reduced in Diabetic Neuropathy and May Be Associated with the Development of Neuropathic Pain'.** *Open Science Framework*. 2016b. [Publisher Full Text](#)
- Humble SR: **Neurosteroids; endogenous analgesics?** PhD Thesis, University of Dundee. 2013. [Reference Source](#)
- Humble SR: **Neurosteroids are reduced in diabetic neuropathy and may be associated with the development of neuropathic pain [version 1; referees: 1 approved, 2 approved with reservations].** *F1000Res*. 2016a; 5: 1923. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Papadopoulos V, Lecanu L: **Translocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotrauma.** *Exp Neurol*. 2009; 219(1): 53–57. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Rupprecht R, Papadopoulos V, Rammes G, *et al.*: **Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders.** *Nat Rev Drug Discov*. 2010; 9(12): 971–988. [PubMed Abstract](#) | [Publisher Full Text](#)
- Schumacher M, Hussain R, Gago N, *et al.*: **Progesterone synthesis in the nervous system: implications for myelination and myelin repair.** *Front Neurosci*. 2012; 6: 10. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Stocco DM, Zhao AH, Tu LN, *et al.*: **A brief history of the search for the Protein(s) involved in the acute regulation of steroidogenesis.** *Mol Cell Endocrinol*. 2017; 441: 7–16. [PubMed Abstract](#) | [Publisher Full Text](#)
- Tokuda K, O'Dell KA, Izumi Y, *et al.*: **Midazolam inhibits hippocampal long-term potentiation and learning through dual central and peripheral benzodiazepine receptor activation and neurosteroidogenesis.** *J Neurosci*. 2010; 30(50): 16788–95. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Zhang LM, Qiu ZK, Chen XF, *et al.*: **Involvement of allopregnanolone in the anti-PTSD-like effects of AC-5216.** *J Psychopharmacol*. 2016; 30(5): 474–81. [PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 20 March 2018

<https://doi.org/10.5256/f1000research.15396.r31739>

© 2018 Todorovic S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Slobodan M. Todorovic

Department of Anesthesiology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 06 June 2017

<https://doi.org/10.5256/f1000research.11924.r23003>

© 2017 Darbon P. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Pascal Darbon

Institut des Neurosciences Cellulaires et Intégratives (INCI), UPR 3212 CNRS, Centre National de la Recherche Scientifique and University of Strasbourg, Strasbourg Cedex, France

The present article is a follow-up of Humble's previous paper in F1000Research (*Humble SR. Neurosteroids are reduced in diabetic neuropathy and may be associated with the development of neuropathic pain* [version 1; referees: 1 approved, 2 approved with reservations]. *F1000Research* 2016, **5**:1923 doi: [10.12688/f1000research.9034.1](https://doi.org/10.12688/f1000research.9034.1)). The current article could be considered as an extended version providing further clarification on involved mechanisms. Therefore to fully

understand the presented results, I recommend reading first the previous article.

However, in order to reach a broader leadership illustration and description could be improved. Figure 1 could be improved by highlighting the difference with Humble's 2016 paper; action sites of Diazepam, Flumazenil and Finasterid could be indicated. Likewise, results description focuses on difference between both mice strains without fully presenting individual results (Finast, Diaz, Flumaz...). This required a strong background in the field.

My last comment concerns the primary effect of diazepam on GABA_AR. The experiment consists in a 2 h incubation and it has been shown (*in vivo* in other brain structure, Zeitler *et al.* Eur J Neurosci, 2016) that Diazepam acts within 15-30 min then is relayed by neurosteroidogenesis. Therefore, it is difficult to conclude on the primary effect alone.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 14 Jun 2017

Stephen Humble, Charing Cross Hospital, Imperial College NHS Healthcare Trust London, London, UK

Dear Prof Darbon,

Thank you for your comments and for taking the time to review the paper. I agree that the illustration and description could be improved and I will do so as per your suggestions. I agree that the brief background description makes the research harder for a broad readership- this is as a result of the article's word limits.

Regarding the 2 hour incubation period for diazepam. This issue was considered at length during the experimental design stage and this is a relevant concern. It is of course true that *in vivo* diazepam acts within 15-30 minutes and that *in vivo* propofol and etomidate may act within seconds when given intravenously. However, previous work (Benkowitz *et al.*, 2007; Gredell *et al.*, 2004) has shown that in brain slice preparations the duration of onset may be much longer in lipophilic compounds such as these because the drug has to diffuse through the slice to reach the GABA_A receptor on the neurone located within the slice. This contrasts to rapid drug delivery via an intact *in vivo* circulation, which may deliver the drug directly to the relevant neurone within seconds to minutes. Taking all this into account it was decided to use a 2 hour incubation period in order to maximise the impact of diazepam and highlight the difference between the diabetic neurones and the wild type. i.e. that diazepam in the presence of flumazenil (benzodiazepine receptor antagonist) had a greater response in the diabetic neurones, which appears to be mediated via upregulated neurosteroidogenesis and could be blocked by finasteride. Finally, I think that these results are not inconsistent with the Zeitler *et al.*, 2016 paper.

Yours sincerely

Stephen Humble

Competing Interests: No competing interests were disclosed.

Reviewer Report 30 May 2017

<https://doi.org/10.5256/f1000research.11924.r22166>

© 2017 Todorovic S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Slobodan M. Todorovic

Department of Anesthesiology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

My major concern with this study is that title and discussion are not relevant to the data presented. There is no justification to link this study to neuropathic pain or painful diabetic neuropathy. Perhaps more appropriate title would be:

“Mitochondrial dysfunction in an animal model of Type 2 diabetes may be involved reduction in neurosteroid synthesis “

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 31 May 2017

Stephen Humble, Charing Cross Hospital, Imperial College NHS Healthcare Trust London, London, UK

Dear Prof Todorovic,

Thank you for taking the time to review the paper. I agree that the title should be changed. I have reworded it as follows in relation to your comments:

“Mitochondrial dysfunction in an animal model of diabetic neuropathy is associated with a reduction of neurosteroid synthesis”

With the benefit of hindsight I realize that linking these data in isolation directly to neuropathic pain and painful diabetic neuropathy is not justified. For the purposes of

brevity full rationale was not explained in as much depth as was required to explain the link fully. If this paper is viewed alongside this other recent paper then the scientific rationale and justification may be understood:

Humble SR: Neurosteroids are reduced in diabetic neuropathy and may be associated with the development of neuropathic pain [version 1; referees: 1 approved, 2 approved with reservations]. F1000Res. 2016a; 5: 1923.

I will make some modifications to the abstract and discussion in relation to your comments as follows:

Abstract section

Old (final sentence):

In diabetic neuropathic pain, mitochondrial dysfunction may play an important role. Enhancing the GABAergic neurosteroid tone could be of potential therapeutic benefit.

New:

In diabetic neuropathy, mitochondrial dysfunction may play an important role. Enhancing the GABAergic neurosteroid tone could be of potential therapeutic benefit.

Discussion section

Old (final sentence):

With reference to diabetic neuropathy, mitochondrial dysfunction may play an important role, and enhancing the GABAergic neurosteroid tone directly or indirectly could be of potential therapeutic benefit.

New:

Considering the findings in this paper alongside previous work (Humble, 2016a) it appears that mitochondrial dysfunction may play an important role in the development of type 2 diabetic neuropathy. In this context, it follows that enhancing the GABAergic neurosteroid tone directly or indirectly could be of potential therapeutic benefit for diabetic neuropathic pain and hypersensitivity.

Yours sincerely

Stephen Humble

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research